Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Web – sheet or filament bases; compositions of bandages; or...
Patent
1998-08-04
1999-10-05
Brouillette, D. Gabrielle
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Web, sheet or filament bases; compositions of bandages; or...
424445, 424449, A61F 1302
Patent
active
059620137
ABSTRACT:
This invention provides monolithic matrix formulations for transdermal administration of molsidomine. The device includes a copolymer of 2-ethylhexyl acrylate, 2-hydroxyethylmethacrylate, and methacrylic acid. The invention also provides transdermal devices having a monolithic matrix made using such a formulation in combination with an active ingredient and a vehicle or vehicle formulation.
REFERENCES:
patent: 3598122 (1971-08-01), Zaffaroni
patent: 4087539 (1978-05-01), Muchowski et al.
patent: 4089969 (1978-05-01), Muchowski et al.
patent: 4097579 (1978-06-01), Muchowski et al.
patent: 4140698 (1979-02-01), Van Horn et al.
patent: 4232038 (1980-11-01), Kluge et al.
patent: 4344943 (1982-08-01), Muchowski
patent: 4347185 (1982-08-01), Muchowski et al.
patent: 4347186 (1982-08-01), Muchowski et al.
patent: 4347187 (1982-08-01), Muchowski et al.
patent: 4353829 (1982-10-01), Thurber et al.
patent: 4397862 (1983-08-01), Mroszzczak et al.
patent: 4454151 (1984-06-01), Waterbury
patent: 4454326 (1984-06-01), Muchowski et al.
patent: 4456759 (1984-06-01), Muchowski et al.
patent: 4457941 (1984-07-01), Ringold et al.
patent: 4458081 (1984-07-01), Muchowski et al.
patent: 4490322 (1984-12-01), Zierenberg
patent: 4496741 (1985-01-01), Doherty
patent: 4505927 (1985-03-01), Muchowski et al.
patent: 4564010 (1986-01-01), Coughlan et al.
patent: 4568343 (1986-02-01), Leeper et al.
patent: 4751087 (1988-06-01), Wick
patent: 4780320 (1988-10-01), Baker
patent: 4873340 (1989-10-01), Muchowski et al.
patent: 4874871 (1989-10-01), Fleming et al.
patent: 4919939 (1990-04-01), Baker
patent: 4956171 (1990-09-01), Chang
patent: 4988822 (1991-01-01), Muchowski et al.
patent: 4994267 (1991-02-01), Sablotsky
patent: 5091182 (1992-02-01), Ong et al.
patent: 5149538 (1992-09-01), Granger et al.
patent: 5308625 (1994-05-01), Wong et al.
patent: 5358715 (1994-10-01), Wong et al.
patent: 5589498 (1996-12-01), Mohr et al.
Guzman et al., "Absolute configuration of 5-benzoyl-1, 2-dihydro-3H-pyrrolo Med. Chem. (1986) 29:589-591.
Muchowski et al., "Synthesis and antiinflammatory and analgesic activity of related compounds" J. Med. Chem. (1985) 28:1037-1049.
Gu et al., "Light degradation of ketorolac tromethamine" Int. J. Pharm. (1988) 41:105-113.
Gu et al., "Kinetics and mechanisms of the autoxidation of ketorolac tromethamine in aqueous solution" Int. J. Pharm. (1988) 41:95-104.
Yu et al., "Percutaneous absorptionof nicardipine and ketorolac in rhesus monkeys" Pharm. Res. (1988) 5(7):457-462.
Buckley et al., "Keterolac-a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential" Drugs (1990) 39:86-109.
Yamada et al., "Mechanismof enhancement of percutaneous absorption of molsidomine by oleic acid" Chem. Pharm. Bull. (1987) 35:3399-3406.
Merck Index, 10th edition, "Molsidomine" (1983) 6087:892.
Asahi et al., "Chemical and kinetic study on stabilities of 3-morpholinosydnonimine and its N-ethoxycarbonyl derivative" Chem. Pharm. BUll. (1971) 19:1079-1088.
Kukovetz et al., "Mechanism of vasodilation by molsidomine" Am. Heart J. (1985) 109:637-640.
Yamada et al., "Enhancement of percutaneous absorption of molsidomine" Chem. Pharm. Bull. (1987) 35(8):3390-3998.
Ostrowski et al., "Pharmacokinetics of molsidomine in humans" Am. Heart J. (1985) 109:641-643.
Alza Corporation Newsletter "Alza pioneers work in transdermal delivery" (1991) 4(1):1-4.
Andrews et al., "Fentanyl-a review" Clin. Anaesthiol. (1983) 1(1):97-122.
Bickers et al., "Epidermis: A site of drug metabolism in neonatal rat skin" Pharmacol. (1982) 21:239-247.
Bucks, "Skin structure and metabolism: Relevance to the design of cutaneous therapeutics" Pharm. Res. (1984) 1:148-153.
Bromage, "The price of intraspinal narcotic analgesia: basic constraints" Anesthesi and Analgesia (1981) 60(7):461-463.
Casale et al., "Induction of human cutaneous mast cell degranulation by opiates nad endogenous opioid peptides: Evidence for opiate and nonopiate receptor participation" J. Aller. Clin. Immunol. (1984) pp. 775-781.
Diebschlag et al., "A double-blind study of the efficacy of topical ketorolac tromethamine gel in the treatment of ankle sprain in comparison to placebo ad etofenamate" J. Clin. Pharmacol. (1990) 30(1):82-89.
Finch et al., "Clinical investigation of the analgesic potency and respiratory depressant activity of fentanyl, a new narcotic analgesic" J. Clin. Pharmacol. (1967) 7(1):46-51.
Fjellner et al., "Potentiation of histamine-induced itch and flare responces in human skin by the enkephalin analogue FK33-824, J-endorphin and morphine" Arch. Derm. Res. (1982) 274:29-37.
TGrosman, "Histamine release from human basophils and isolated rat mast C induced by ketobemidone, pethidine and the spasmolytic A29" Acta Pharmacol. et Toxicol. (1982)50:78-80.
Hermens et al., "Comparison of histamine release in human skin mast cells induced by morphine, fentanyl, and oxymorphine" Anesthesiology (1985) 62:124-129.
Liaw et al., "Percutaneous absorption of ketorolac topical gel formulations vehicle effects and in-vitro-in-vivo correlations" J. Pharm. Sci. (1987) 76(11):S280.
Menardo et al., "Skin test reactivity in infancy" Aller. Clin. Immunol. (1985) 75(6):646-651.
Martin et al., "Sensitization by in vitro incubation with morphine of the myenteric plexus-longitudinal msucle preparation" J. Pharmacol. (1982) 13(1):3-10.
Palestine et al., "Skin manifestations of pentazocine abuse" Am. Acad. Dermatol. (1980) 2(1):47-55.
Philbin et al., "Histamine release with intravenous narcotics: Protective effects of H1 and H1-receptor antagonists" Klin. Wochenschr. (1982) 60:1056-1059.
Ponte, "A suspected case of codeine-induced erythema mutli-forme" Drug Intelligence and Clinical Pharmacy (1983) 17:128-130.
Reiz et al., "Side-effects of epidural morphine" Lancet (Jul. 26, 1980) 2:203-204.
Roy et al., "Concepts in transdermal delivery of narcotics II: In vivo permeation of suffentanil and fentanyl through human skin" Pharm. Res. (1986) 3(5):54S (Abstract No. 60).
Saucedo et al., "Morphine-induced skin wheals: A possible model for the study of histamine release" Clin. Pharmacol. Ther. (1985) 38(4):365-370.
Schnur, "Morphine tolerance and sensitization in the hamster" Pharmacol. Biochem. & Behav. (1985) 22:157-158.
Shipton, "Pruritus-a side effect of epidural fentanyl for postoperative analgesia" SA Med. J. (1984) 66:61-62.
Wang et al., "Suppressive effects of oral ketotifen on skin responses to histamine, codeine, and allergen skin tests" Ann. Aller. (1985) 55:57-61.
Wilham et al., "Concepts in transdermal delivery of narcotics I: Enzymatic activity in hairless mouse skin and human epidermal homogenates" Pharm. Res. (1986) 3(5):54S (Abstract No. 59).
Wong et al., "A randomized double-blind evaluation of ketorolac tromethamine for postoperative analgesia in ambulatory surgery patients" Anesthesiology (1993) 78(1):6-14.
Wong et al., "An evaluation of ketorolac as sole analgesic after outpatient surgery" ANesthesiology (1972) 77(Supplement3A):A6.
Nguyen Thuytien N.
Wong Ooi
Brouillette D. Gabrielle
Cygnus Inc.
Horne Angela P.
McClung Barbara G.
LandOfFree
Monolithic matrix transdermal delivery system for administering does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monolithic matrix transdermal delivery system for administering , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monolithic matrix transdermal delivery system for administering will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1168623